Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fate Therapeutics
Eli Lilly and Company
Institut Paoli-Calmettes
OHSU Knight Cancer Institute
Fate Therapeutics
Yale University
NKGen Biotech, Inc.
National Cancer Institute (NCI)
Orano Med LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
ARCAGY/ GINECO GROUP